This technology is a PBA-conjugated lipid nanoparticle platform that improves bioactive RNA transfection efficiency.
Lipid nanoparticles (LNPs) are used to deliver RNA therapies to cells. Unfortunately, they have low efficiency due to endosomal degradation, with only 2-4% of the encapsulated material making it into cells. LNPs also have inefficient cytosolic unpacking, meaning they cannot degrade and release their encapsulated material in the cytosol. There is a need to develop LNPs that can better escape endosomal degradation and release RNA into the cytosol.
This technology is a phenylboronic acid (PBA)-conjugated lipid nanoparticle (LNP) that enhances RNA delivery efficiency in cells. These LNPs overcome intracellular barriers to gene delivery by switching between hydrophilic and hydrophobic states in response to pH, thereby stabilizing the particles to aid endosomal escape while promoting cytosolic unpacking of cargo. These properties allow the PBA-conjugated LNPs to have much greater efficiency of RNA delivery than unconjugated LNPs. Additionally, these nanoparticles can form reversible bonds with groups found in sugars, expanding the use of this technology to a range of applications that require selective targeting, such as targeted cancer therapies.
This technology has been validated with human cancer cell lines.
Patent Pending
IR CU26135
Licensing Contact: Dovina Qu
